Annovis Bio Inc (ANVS) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03615A1088
Annovis Bio, Inc. (NYSE: ANVS) is a promising clinical stage drug platform company dedicated to creating medications for neurodegenerative conditions.
Their most prominent product in development is Buntanetap, currently undergoing Phase 3 clinical trials to potentially address Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative ailments.
Additionally, Annovis Bio is actively working on ANVS405 to aid in brain protection following traumatic brain injury or stroke, as well as exploring ANVS301, currently in Phase I clinical trials, with a focus on enhancing cognitive function in the later stages of AD and dementia.
Founded in 2008 and headquartered in Berwyn, Pennsylvania, Annovis Bio aims to make significant strides in treating neurological disorders. More information about the company can be found on their website: https://www.annovisbio.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ANVS Stock Overview
| Market Cap in USD | 140m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2010-02-12 |
ANVS Stock Ratings
| Growth 5y | -2.27 |
| Fundamental | -66.4 |
| Dividend | - |
| Rel. Performance vs Sector | -10.92 |
| Analysts | 4.20/5 |
| Fair Price Momentum | 4.00 USD |
| Fair Price DCF | - |
ANVS Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
ANVS Growth Ratios
| Growth 12m | -67.78% |
| Growth Correlation 12m | -38% |
| Growth Correlation 3m | 1% |
| CAGR 5y | -14.81% |
| Sharpe Ratio 12m | -0.60 |
| Alpha vs SP500 12m | -110.90 |
| Beta vs SP500 5y weekly | 1.73 |
| ValueRay RSI | 10.52 |
| Volatility GJR Garch 1y | 239.94% |
| Price / SMA 50 | -51.31% |
| Price / SMA 200 | -53.56% |
| Current Volume | 420.4k |
| Average Volume 20d | 955k |
External Links for ANVS Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 09, 2024, the stock is trading at USD 4.82 with a total of 420,355 shares traded.
Over the past week, the price has changed by -21.11%, over one month by -57.94%, over three months by -55.54% and over the past year by -67.43%.
According to ValueRays Forecast Model, ANVS Annovis Bio Inc will be worth about 4.5 in May 2025. The stock is currently trading at 4.82. This means that the stock has a potential downside of -5.81%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 35.4 | 634 |
| Analysts Target Price | 46 | 854 |
| ValueRay Target Price | 4.5 | -5.81 |